IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
The adenosine pathway is a source of emerging targets in cancer immunotherapy. IPH5201 is a mAb that targets the adenosine pathway by blocking human CD39 enzymatic activity. In this first-in-human, phase 1 study, IPH5201 as monotherapy or in combination with durvalumab was well tolerated with a manageable safety profile in patients with advanced solid tumors. Preliminary evidence for disease stabilization and reduction of tumoral CD39 enzymatic activity were observed.
Authors
- Meredith McKean (ORCID: https://orcid.org/0000-0003-0944-7418)
- Vicky Barnhart
- Eric Tu
- Raymond Mager (ORCID: https://orcid.org/0009-0004-6753-7416)
- Martina Imbimbo (ORCID: https://orcid.org/0000-0003-2521-7540)
- Chunling Fan (ORCID: https://orcid.org/0009-0001-9259-7064)
- Carine Paturel
- Yun He (ORCID: https://orcid.org/0000-0002-0077-3113)
- Steven Eck (ORCID: https://orcid.org/0000-0001-6074-8430)
- Paula G. Fraenkel (ORCID: https://orcid.org/0000-0001-8894-0117)
- Antoîne Italiano (ORCID: https://orcid.org/0000-0002-8540-5351)
- Elina Murtomaki
- Benedito A. Carneiro (ORCID: https://orcid.org/0000-0002-5468-1126)
- Zachary A. Cooper (ORCID: https://orcid.org/0000-0003-1059-0940)
- Patricia Martín-Romano (ORCID: https://orcid.org/0000-0002-3923-5160)
- Teresa Macarulla (ORCID: https://orcid.org/0000-0002-5856-4082)
- Antoine Hollebecque (ORCID: https://orcid.org/0000-0003-2869-7551)
- John D. Powderly (ORCID: https://orcid.org/0000-0002-7608-0380)
- Arsène‐Bienvenu Loembé (ORCID: https://orcid.org/0009-0001-2557-8170)
- Eduardo Castañón Álvarez (ORCID: https://orcid.org/0000-0003-2957-4414)
- Agnes Boyer Chamard
Institutions
- AstraZeneca (United Kingdom) (GB)
- Hebron University (PS)
- Université de Bordeaux (FR)
- Brown University (US)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire Vaudois (CH)
- AstraZeneca (South Korea) (KR)
- Carolina BioOncology Institute (US)
- Massachusetts Medical Society (US)
- Sarah Cannon (US)
- AstraZeneca (Brazil) (BR)
- Gobierno de Navarra (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Institut Bergonié (FR)
- Clinica Universidad de Navarra (ES)
- Tennessee Oncology (US)
- Innate Pharma (France) (FR)
- AstraZeneca (United States) (US)
- Lifespan (US)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0361
- Citations
- 1
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.12
Funders
- AstraZeneca